CPMD (Cannapharmarx) Beneish M-Score : 0.00 (As of Dec. 13, 2024)

View and export this data going back to 1999. Start your Free Trial

What is Cannapharmarx Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Cannapharmarx's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Cannapharmarx was 0.00. The lowest was 0.00. And the median was 0.00.

Cannapharmarx Beneish M-Score Historical Data

The historical data trend for Cannapharmarx's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannapharmarx Beneish M-Score Chart

Cannapharmarx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beneish M-Score

Get a 7-Day Free Trial

Cannapharmarx Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Beneish M-Score	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Cannapharmarx's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Cannapharmarx's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cannapharmarx's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannapharmarx's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Cannapharmarx's Beneish M-Score falls into.

Cannapharmarx Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Cannapharmarx for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 *

0.528 *

0.404 *

0.892 *

0.115 *

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 *

4.679 *

0.327 *

This Year (Sep24) TTM:

Last Year (Sep23) TTM:

Total Receivables was $0.27 Mil.
Revenue was 0.312 + 0 + 0.026 + 0 = $0.34 Mil.
Gross Profit was -0.356 + 0 + -0.437 + 0 = $-0.79 Mil.
Total Current Assets was $1.50 Mil.
Total Assets was $11.68 Mil.
Property, Plant and Equipment(Net PPE) was $5.67 Mil.
Depreciation, Depletion and Amortization(DDA) was $-0.01 Mil.
Selling, General, & Admin. Expense(SGA) was $0.29 Mil.
Total Current Liabilities was $22.50 Mil.
Long-Term Debt & Capital Lease Obligation was $5.76 Mil.
Net Income was 0.188 + 5.362 + -11.716 + 7.545 = $1.38 Mil.
Non Operating Income was 1.336 + 6.443 + -10.349 + 7.367 = $4.80 Mil.
Cash Flow from Operations was -0.541 + -0.428 + -0.549 + -1.304 = $-2.82 Mil.

Total Receivables was $0.05 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $0.05 Mil.
Total Assets was $5.16 Mil.
Property, Plant and Equipment(Net PPE) was $5.10 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.30 Mil.
Selling, General, & Admin. Expense(SGA) was $5.14 Mil.
Total Current Liabilities was $20.23 Mil.
Long-Term Debt & Capital Lease Obligation was $5.56 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(0.271 / 0.338)	/	(0.054 / 0)
	=	0.801775	/
	=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(0 / 0)	/	(-0.793 / 0.338)
	=		/	-2.346154
	=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (1.497 + 5.666) / 11.681)	/	(1 - (0.054 + 5.102) / 5.156)
	=	0.386782	/	-0
	=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	0.338	/	0
	=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(0.297 / (0.297 + 5.102))	/	(-0.009 / (-0.009 + 5.666))
	=	0.05501	/	-0.001591
	=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(0.287 / 0.338)	/	(5.14 / 0)
	=	0.849112	/
	=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((5.763 + 22.503) / 11.681)	/	((5.557 + 20.229) / 5.156)
	=	2.419827	/	5.001164
	=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(1.379 - 4.797	-	-2.822)	/	11.681
	=	-0.051023

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Cannapharmarx Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Cannapharmarx's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Cannapharmarx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannapharmarx Inc (OTCPK:CPMD) » Definitions » Beneish M-Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

888 3rd Street SW, Suite 3600, Calgary, AB, CAN, T2P 5C5

Website

https://www.cannapharmarx.com

Cannapharmarx Inc is involved in the cannabis sector. The company negotiates, acquires, and develops various cannabis cultivation projects throughout Canada. Its three projects include the Hanover Project; the Great Northern Project, and the Acquisition of Sunniva Medical.

Executives

Anthony Michael Panek	director	95 SOUTH STATE STREET, SUITE 2300, SALT LAKE CITY UT 84111
Dominic Colvin	director, officer: Chief Executive Officer	C/O CANNAPHARMARX, INC., 2 PARK PLAZA, SUITE 1200-B, IRVINE CA 92614
John Hamilton Cassels	officer: Chief Financial Officer	SUITE 500, 209 8TH AVENUE SW, CALGARY A0 T2P 1B8
Richard Dale Orman	director	302, 3204 RIDEAU PLACE SW, CALGARY A0 T2S1Z2
Andrew Clifford Steedman	officer: Chief Operating Officer	1131 RIVERDALE AVE SW, CALGARY A0 T2S 0Y9
Marc R Branson	director	977 KEITH ROAD, WEST VANCOUVER A1 V7T 1M6
Gary J Herick	10 percent owner	7609 RALSTON ROAD, ARVADA CO 80002
James F Samuelson	director	PO BOX 22, NEWPORT BEACH CA 92662
Matthew Nicosia	director, 10 percent owner	2 PARK PLAZA, SUITE 400, IRVINE CA 92614
Robert M Liess	director	2602 W. SAM ALLEN RD., PLANT CITY FL 33565
Mathew D Sherwood	director	P.O. BOX 4375, DILLON CO 80435
James E Smeeding	director	4029 GILBERT AVENUE, DALLAS TX 75219
Elie M Khalife	director	9447 E. CROSS CREEK STREET, WICHITA KS 67206
Steven J Rule	director	C/O CANNAPHARMARX, INC., ONE COLLINS DRIVE, SUITE 100, CARNEYS POINT NJ 08069
Alexander R Giaquinto	director	120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920